TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A systematic review and meta-analysis covering 19 studies and 15,920,970 participants found ADHD was associated with higher all-cause mortality and higher risks of suicide, injury and natural-cause death. ADHD medication use was associated with lower all-cause mortality, but that finding came from only three studies and cannot establish that medication caused the difference.
A systematic review and meta-analysis of nearly 16 million people found that attention-deficit/hyperactivity disorder (ADHD) was associated with a 71% higher rate of all-cause mortality than in people without ADHD, according to research published in JAMA Network Open. The authors also reported higher rates of suicide, injury and natural-cause death, while a separate analysis linked ADHD medication use with lower mortality but was based on just three studies.
The review included 19 studies with a combined 15,920,970 participants; 63.9% were male. Twelve studies provided results for the researchers’ meta-analyses. The team, led by Joshua Stott, PhD, of University College London, reported a hazard ratio of 1.71 for all-cause mortality among people with ADHD (95% confidence interval 1.31 to 2.24). A hazard ratio compares the rate at which an outcome occurs over time between groups; it does not give an individual’s absolute likelihood of dying.
The analysis also found higher mortality associated with suicide (hazard ratio 1.89), intentional or unintentional injury (1.55), and natural causes (1.27). The medication analysis found an association with lower all-cause mortality (hazard ratio 0.75). The researchers cautioned that this result is not proof that medication itself reduces mortality: treated and untreated groups may differ in health care access, illness severity, socioeconomic circumstances, adherence and other factors.
ADHD definitions varied across the studies. Researchers included participants identified through diagnostic criteria, self-identification, trait measures or ADHD polygenic risk scores. The authors reported substantial variation between studies in several analyses, although the included studies consistently found higher mortality in ADHD groups. They said differences in the size of the associations may help explain that variation.
Mortality Findings Point to Care Gaps
The findings add to evidence that ADHD is associated with health risks extending beyond its core symptoms. The authors described several possible pathways, including impulsivity and risk-taking contributing to injuries; co-occurring conditions such as depression contributing to suicide risk; and smoking, alcohol use, cardiovascular disease, metabolic disorders or barriers to health care contributing to natural-cause mortality. These are possible explanations discussed by the researchers, not mechanisms proven by this review.
For readers, the results support attention to timely recognition of ADHD and access to appropriate care, while avoiding the conclusion that an ADHD diagnosis predicts an individual’s lifespan. The study reports group-level associations, not a forecast for any one person. The medication result is especially limited: three observational studies cannot establish that treatment prevents death, and the researchers said residual confounding may affect the estimate.
Stott told MedPage Today that the findings do not mean everyone with ADHD will die young or that higher mortality is inherent or impossible to change. He said the results underscore the importance of accurate diagnosis and treatment access. That distinction matters: the review identifies an association and points to care questions, but does not test whether a particular intervention changes mortality.
As an affiliate, we earn on qualifying purchases.
How Researchers Built the Review
The researchers assessed quantitative studies of mortality among people with ADHD across age groups, including peer-reviewed research available through July 2025. They conducted five meta-analyses: all-cause mortality, suicide, injury, natural-cause mortality, and all-cause mortality among people using ADHD medication. The number of contributing studies differed by outcome: nine for all-cause mortality, five for suicide, four for injury, three for natural-cause mortality and three for the medication analysis.
The report arrives amid concerns about ADHD being missed or diagnosed late, particularly in adults. Jeffrey Newcorn, MD, of the Icahn School of Medicine at Mount Sinai, who was not involved in the study, told MedPage Today that many adults receive their diagnosis in adulthood and that some diagnosed adults do not receive treatment. The article cited CDC estimates of 15 million U.S. adults with ADHD and 7 million children ages 3 to 17 with a diagnosis; those figures describe U.S. prevalence, not the study’s international participant group.
Earlier research cited by the report had also found elevated mortality among people with ADHD. Some studies have suggested a six- to seven-year life-expectancy gap, but that figure is not the main estimate produced by this meta-analysis and should not be read as a prediction for each person with ADHD.
“These findings do not suggest that everyone with ADHD will die young, nor do they suggest that increased mortality is impossible to change or inherent to ADHD.”
— Joshua Stott, PhD, lead author, speaking to MedPage Today
ADHD safety and injury prevention devices
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Limits of the Mortality Estimates
The review cannot show that ADHD directly causes the higher mortality rates, nor can it identify how much each possible pathway contributes. The studies differed in how they defined ADHD, the populations they covered and access to care. The authors reported substantial heterogeneity in the all-cause, suicide and injury analyses, among others; the size of the association varied even though the direction was consistent across studies.
The apparent lower mortality associated with medication remains particularly uncertain. It was based on three studies and may reflect differences between people who receive treatment and those who do not, rather than a protective effect of the medication. The review does not establish which medications, treatment duration or patient groups might be associated with the result. Gender imbalances in many studies and cross-cultural differences in diagnosis and care were also noted by the authors.
The results also do not give an absolute mortality risk for an individual, a precise life-expectancy estimate, or a measure of how much timely diagnosis or treatment might change outcomes. The source material does not report a trial testing whether ADHD care reduces deaths.
As an affiliate, we earn on qualifying purchases.
Questions for Future ADHD Studies
The immediate next step is further research that can test the patterns in larger, more comparable groups and clarify whether treatment is associated with changes in mortality over time. Studies would need to account for differences in health status, psychiatric conditions, socioeconomic circumstances and access to care, as well as the reasons some people receive treatment and others do not.
The review itself does not announce a new trial or a policy change. Its findings are a synthesis of research available through July 2025, so future studies may refine the estimates and help distinguish among possible pathways. For now, the authors’ message is that higher mortality at the group level warrants attention to accurate diagnosis and care access, while the medication association should be treated cautiously rather than as evidence that treatment prevents death.
ADHD awareness and health monitoring products
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the review find about ADHD and mortality?
Across the included studies, ADHD was associated with a 71% higher rate of all-cause mortality (hazard ratio 1.71). The review also found higher rates associated with suicide, injury and natural causes. These are group-level associations, not predictions for individual people.
Does the study show that ADHD medication lowers the risk of death?
No. Medication use was associated with lower all-cause mortality in an analysis of three studies, but the result cannot establish cause and effect. Differences in health care access, severity, adherence and other factors could help explain the association.
Does ADHD mean someone will die younger?
No. The analysis describes differences in mortality rates between groups and does not determine an individual’s lifespan. Lead author Joshua Stott said the findings do not mean everyone with ADHD will die young or that increased mortality is inherent to ADHD.
What causes the higher mortality rates reported?
The review did not establish a single cause. Its authors discussed possible links involving injury risk, co-occurring mental health conditions, smoking or alcohol use, health care barriers, and cardiovascular or metabolic conditions. These explanations remain possibilities, not proven causes of the overall association.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
